View in EDS PDF Full Text

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.

Saved in:
Bibliographic Details
Title: Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
Authors: Feelders RA; Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands., Fleseriu M; Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, United States., Kadioglu P; Division of Endocrinology, Metabolism and Diabetes, Cerrahpasa Medical Faculty, Istanbul University - Cerrahpasa, Istanbul, Türkiye., Bex M; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium., González-Devia D; Departamento de Medicina Interna, Sección de Endocrinologia, Hospital Universitario Fundación Santa Fé de Bogotá, Bogota, Colombia., Boguszewski CL; Department of Internal Medicine, Endocrine Division (SEMPR), Federal University of Paraná, Curitiba, Parana, Brazil., Yavuz DG; Section of Endocrinology and Metabolism, Marmara University School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul, Türkiye., Patino H; Global Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States., Pedroncelli AM; Recordati AG, Basel, Switzerland.; Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland., Maamari R; Global Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States., Chattopadhyay A; Global Medical Affairs, Novartis Healthcare Private Limited, Hyderabad, Telangana, India., Biller BMK; Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, United States., Pivonello R; Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy.
Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Oct 09; Vol. 14, pp. 1165681. Date of Electronic Publication: 2023 Oct 09 (Print Publication: 2023).
Publication Type: Clinical Trial, Phase II; Multicenter Study; Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37876540
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Feelders+RA%22">Feelders RA</searchLink>; Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Fleseriu+M%22">Fleseriu M</searchLink>; Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, United States.<br /><searchLink fieldCode="AU" term="%22Kadioglu+P%22">Kadioglu P</searchLink>; Division of Endocrinology, Metabolism and Diabetes, Cerrahpasa Medical Faculty, Istanbul University - Cerrahpasa, Istanbul, Türkiye.<br /><searchLink fieldCode="AU" term="%22Bex+M%22">Bex M</searchLink>; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22González-Devia+D%22">González-Devia D</searchLink>; Departamento de Medicina Interna, Sección de Endocrinologia, Hospital Universitario Fundación Santa Fé de Bogotá, Bogota, Colombia.<br /><searchLink fieldCode="AU" term="%22Boguszewski+CL%22">Boguszewski CL</searchLink>; Department of Internal Medicine, Endocrine Division (SEMPR), Federal University of Paraná, Curitiba, Parana, Brazil.<br /><searchLink fieldCode="AU" term="%22Yavuz+DG%22">Yavuz DG</searchLink>; Section of Endocrinology and Metabolism, Marmara University School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul, Türkiye.<br /><searchLink fieldCode="AU" term="%22Patino+H%22">Patino H</searchLink>; Global Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Pedroncelli+AM%22">Pedroncelli AM</searchLink>; Recordati AG, Basel, Switzerland.; Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Maamari+R%22">Maamari R</searchLink>; Global Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Chattopadhyay+A%22">Chattopadhyay A</searchLink>; Global Medical Affairs, Novartis Healthcare Private Limited, Hyderabad, Telangana, India.<br /><searchLink fieldCode="AU" term="%22Biller+BMK%22">Biller BMK</searchLink>; Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, United States.<br /><searchLink fieldCode="AU" term="%22Pivonello+R%22">Pivonello R</searchLink>; Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101555782%22">Frontiers in endocrinology</searchLink> [Front Endocrinol (Lausanne)] 2023 Oct 09; Vol. 14, pp. 1165681. <i>Date of Electronic Publication: </i>2023 Oct 09 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Multicenter Study; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101555782 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1664-2392 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216642392%22">16642392 </searchLink><i>NLM ISO Abbreviation: </i>Front Endocrinol (Lausanne) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37876540
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fendo.2023.1165681
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1165681
    Titles:
      – TitleFull: Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Feelders RA
      – PersonEntity:
          Name:
            NameFull: Fleseriu M
      – PersonEntity:
          Name:
            NameFull: Kadioglu P
      – PersonEntity:
          Name:
            NameFull: Bex M
      – PersonEntity:
          Name:
            NameFull: González-Devia D
      – PersonEntity:
          Name:
            NameFull: Boguszewski CL
      – PersonEntity:
          Name:
            NameFull: Yavuz DG
      – PersonEntity:
          Name:
            NameFull: Patino H
      – PersonEntity:
          Name:
            NameFull: Pedroncelli AM
      – PersonEntity:
          Name:
            NameFull: Maamari R
      – PersonEntity:
          Name:
            NameFull: Chattopadhyay A
      – PersonEntity:
          Name:
            NameFull: Biller BMK
      – PersonEntity:
          Name:
            NameFull: Pivonello R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 10
              Text: 2023 Oct 09
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 1664-2392
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Frontiers in endocrinology
              Type: main
ResultId 1